New York, Oct 7 (SocialNews.XYZ) Researchers have demonstrated that RNA terminated by hepatitis-C drug Sofosbuvir may be more effective against the Covid-19 virus.
The results, published in the journal Scientific Reports, support the use of the USFDA-approved hepatitis-C drug EPCLUSA -- Sofosbuvir/Velpatasvir -- in combination with other antiviral drugs in Covid-19 clinical trials.
The SARS-CoV-2 exonuclease-based proof reader maintains the accuracy of viral RNA genome replication to sustain virulence.
Any effective antiviral targeting the SARS-CoV-2 polymerase must therefore display a certain level of resistance to this proof reading activity, according to the researchers.
"We found that the RNA terminated by Sofosbuvir resists removal by the exonuclease to a substantially higher extent than RNA terminated by Remdesivir, another drug being used as a Covid-19 therapeutic," said the study authors from Columbia University in the US.
The new study builds upon earlier work the researchers have conducted.
Last January, before Covid-19 reached pandemic level, the team posited that EPCLUSA might inhibit SARS-CoV-2, the virus responsible for Covid-19.
Their reasoning was based on the analysis of the molecular structures and activities of hepatitis-C viral inhibitors and a comparison of hepatitis-C virus and coronavirus replication.
In a study, the researchers showed that the active drug Sofosbuvir triphosphate is incorporated by SARS-CoV and SARS-CoV-2 polymerases, shutting down the polymerase reaction.
A polymerase is an enzyme that synthesizes long chains of polymers or nucleic acids.
Other investigators have since demonstrated the ability of Sofosbuvir to inhibit SARS-CoV-2 replication in lung and brain cells.
Currently, Covid-19 clinical trials with a number of hepatitis-C drugs such as EPCLUSA and the combination of Sofosbuvir and Daclatasvir (which is similar to Velpatasvir) are ongoing in several countries.
The research team noted that a recent preprint from the University of California Berkeley indicates that a combination of Remdesivir and EPCLUSA increases Remdesivir's efficacy 25-fold in inhibiting the Covid-19 virus.
"These results offer a molecular basis supporting the study of EPCLUSA in combination with Remdesivir for Covid-19 clinical trials," the team concluded.
Source: IANS
About Gopi
Gopi Adusumilli is a Programmer. He is the editor of SocialNews.XYZ and President of AGK Fire Inc.
He enjoys designing websites, developing mobile applications and publishing news articles on current events from various authenticated news sources.
When it comes to writing he likes to write about current world politics and Indian Movies. His future plans include developing SocialNews.XYZ into a News website that has no bias or judgment towards any.
He can be reached at gopi@socialnews.xyz